Ben Carson, Sr., M.D.
Senior Advisor
Ben Carson, Sr., is a world-renowned neurosurgeon and former Secretary of the U.S. Department of Housing and Urban Development. Galectin Therapeutics has engaged Dr. Carson to increase awareness of the company, including its ongoing Phase 2b/3 NAVIGATE clinical trial in NASH cirrhosis, its continuing research in combination with cancer immunotherapy, and its potential in addressing other fibrotic diseases. Dr. Carson is also assisting in the formation of a scientific advisory committee for Galectin Therapeutics, recruiting potential members of the committee, and identifying potential strategic commercial and academic partners for Galectin.
Dr. Carson became the Director of Pediatric Neurosurgery at the Johns Hopkins Children’s Center in 1984 at age 33, the youngest chief of pediatric neurosurgery in the United States until that time. At his 2013 retirement from medicine, he was professor of neurosurgery, oncology, plastic surgery, and pediatrics at the Johns Hopkins School of Medicine. He holds a B.A. in psychology from Yale University, an M.D. from the University of Michigan Medical School, and numerous honorary degrees and national merit citations, including the Presidential Medal of Freedom.
Dr. Ben Carson on the potential behind Galectin Therapeutics
...that caused me to start looking into [the science behind Galectin Therapeutics], and really seeing that some of the possibilities of being able to inhibit things like the deleterious protein complex like galectin-3, which is significant in so many types of pathologies.... And it seemed like it was something that people really weren't paying a lot of attention to, even though it potentially impacts tens of millions of people.Ezra R. Lowe, Ph.D.
Vice President, Clinical and Preclinical Pharmacology
Ezra Lowe brings his depth of experience in clinical pharmacology, drug metabolism, and pharmacokinetics to his role as Executive Director, Clinical and Preclinical Pharmacology at Galectin Therapeutics. He has a broad base of experience working with various drug formats across diverse array of therapeutic areas. Prior to joining Galectin Therapeutics, Ezra was Senior Director, Clinical Pharmacology in Global R&D with the Bausch Health Companies, where he was responsible for the execution of clinical pharmacology strategy across all companies of Bausch Health, including Salix Pharmaceuticals, Bausch + Lomb, and Ortho Dermatologics. Before that, he held Clinical and Nonclinical Pharmacology positions at Salix Pharmaceuticals, Bausch +Lomb, and Valeant Pharmaceuticals International, Inc. and spent time as Lead Scientist in Biotransformation and Toxicology at The Dow Chemical Company.
In the course of his career, he has completed 10 different global drug approvals, and he was twice awarded the Bausch Health CEO award.
Ezra holds a B.A. in Chemistry from Colgate University and a Ph.D. in Pharmacology from the University of Michigan. He is also an alumnus of the McKinsey Black Executive Leadership Program.